pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
Eisai is a pharma organization headquartered in Tokyo, JP. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Epilepsy, colorectal cancer, melanoma, hepatocellular carcinoma, Amyotrophic Lateral Sclerosi
Tokyo, Japan, JP HQ
41 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
eribulin mesylate + erlotinib
Phase 2 · small molecule · Non-small Cell Lung Cancer
eribulin mesylate + erlotinib for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Eisai Co., with 1 ClinicalTrials.gov record(s).
Internal code E7389-G000-205
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Eisai Co.,
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non-small Cell Lung Cancer
- Status
- completed
- Trials
- 1